Chemclin’s new Vitamin D assay provides components for in-vitro quantitative determination of 25-Hydroxy Vitamin D (25-OH Vitamin D) in human serum by a competitive chemiluminescent assay method.
Chemclin’s Anti-TB assay provides components for in-vitro qualitative determination of Antibody to Mycobacterium Tuberculosis (Anti-TB) in human serum or plasma by an indirect chemiluminescent assay method.
Applied and effortless simplicity of Burkert products have always been something to rely on – now we have added pure flexibility to the list of standards you can expect.
Complies with American College of Rheumatology (ACR) ANA Position Statement.
Randox Laboratories has further expanded its market presence in the United States, having been awarded a major supplier agreement with Novation, the leading health care supply chain expertise, analytics and contracting company.
Elevated levels of Lipoprotein(a), (Lp(a)), are considered to be both a causal risk factor and major independent genetic marker of atherosclerotic disorders. What differentiates Lipoprotein(a) testing is that the association between higher Lipoprotein(a) levels and increased CVD risk is continuous and does not depend on raised LDL levels or non-HDL cholesterol, or other CVD risk factors.
As a more sensitive maker of renal dysfunction Randox Cystatin C offers several advantages over traditional creatinine assays.
Randox has developed a versatile range of clinical chemistry analyzers with real cost saving in mind.
NuAire offers a full line of Centrifuges, the Prism™ Mini is a reliable, compact, and economical personal Micro-centrifuge ideal for quick spins that can be used for a wide range of molecular biology protocols. Prism™ Mini works out of the box with a maintenance-free drive system and advanced design providing quiet operation and proper ventilation protecting temperature-sensitive samples.
These couplings are LinkTech's newest polypropylene couplings available now.
NuAire’s Glacier -86°C Ultralow Temperature Freezers provides laboratory professionals a safe, reliable freezer that they can depend on. Each freezer is designed with the most advanced features and benefits available for research, laboratory work, clinical and industrial applications, and has unmatched economical storage, providing the best value found in an ultralow freezer.
NuAire offers both Direct Heat and Water Jacket CO2 Incubators assuring the highest level of performance and dependability for optimum growth conditions.
NuAire’s AireGard ES NU-201 Table Top and NU-301 Console Horizontal Laminar Airflow Hoods provide a HEPA filtered clean work area that is ideal for operations requiring a particle-free, bacteria-free, clean air environment. The Class 5 clean work area offers an excellent work space for small laboratory appliances, microscopes, pipetting, sterile drug preparations, IV admixture preparation, or any application requiring work-in-progress protection from outside potentially harmful contaminants.
Experience Ergonomics™. Work comfortably with NuAire Biosafety Cabinets.
These couplings are LinkTech's smallest connectors yet.
These couplings are LinkTech's first dual set couplings.
Recently, the International Medical Reference Laboratory Proficiency Testing Results (RELA2013) has been published. The projects of MAKER all meet the requirements. Since 2008, MAKER has participated RELA experiments six years in a row, and the projects have been all qualified.
As the first company obtained CNAS medical reference laboratory accreditation in China, Maker provide hundreds of high-quality products to satisfy the different needs from customers.
The blood coagulation system of MAKER, provides integrated solutions and meets various demands of different clinical labs.
IS 1200 Automatic Chemiluminescence Immunoassay System provides systematic solution for lab, integrating instrument, reagent, calibrator, and control.
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information and services, today announced that its Focus Diagnostics products business has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa™ HSV 1 & 2 Direct molecular test on the 3M Integrated Cycler.
hc1.com®, the Healthcare Relationship CloudTM company, and Beckman Coulter Diagnostics, a global leader in developing clinical diagnostic products that help advance and optimize the laboratory, announced a strategic partnership to deliver innovative technology to laboratories that turn large amounts of clinical data into actionable insights that transform how labs manage their business and their contributions to improving healthcare.
The DRG:Hybrid-XL® will be showcased as the centerpiece of DRG International’s display at the 2014 AACC conference in Chicago, IL.
DRG International, a leading international medical diagnostic company, will showcase its DRG Hepcidin 25 (bioactive) ELISA Kit (EIA-5258) at the 2014 AACC in Chicago, IL from July 27-31.
DRG International, a leading international medical diagnostic company, will showcase its DRG Aldosterone ELISA Kit at the 2014 AACC in Chicago, IL from July 27-31.
Diazyme Laboratories today announced that the U.S. Food and Drug Administration (FDA) has granted 510(K) clearance to market its Vitamin D assay for Clinical Chemistry Analyzers.
These couplings are LinkTech's newest products that are set to hit the market very soon.
COLA, the largest private accreditor of medical laboratories serving more than 8,000 across the U.S., successfully concluded its 2014 Leadership Summit in April.
The nation’s healthcare system -- and with it, the laboratory community – is undergoing a period of tremendous change as The Affordable Care Act begins implementation and new healthcare delivery models such as The Patient-Centered Medical Home (PCMH) and Accountable Care Organizations (ACOs) proliferate.
COLA Inc., based in Columbia, MD, an independent, nonprofit laboratory CLIA-accreditation organization, accrediting more than 7,000 clinical diagnostic labs on July, 2013, launched a new education subsidiary, COLA Resources Inc. (CRI®), whose mission is to “Provide educational & consultative services aimed at improving laboratory medicine and patient care.”
As a leading educator in laboratory medicine, COLA Resources Inc.’s (CRI®) goal is to continually update our education platform to reflect and support education regarding changes in regulatory requirements.
Attending the CRI® Symposium for Clinical Laboratories, affords participants the opportunity to participate in discussions centered on EDUCATION FOR LABORATORY EXCELLENCE – making a positive impact for quality patient care. This year’s symposium will be held October 15-18, 2014 at the Buena Vista Palace Hotel & Spa Lake Buena Vista (Orlando), FL. Participants can attend a wide selection of educational sessions, earn up to 20 CME or P.A.C.E® credits, network with other healthcare professionals and visit the exhibit hall featuring the latest laboratory technology, equipment and supplies.
The DRG 25-OH Vitamin D (total) ELISA, an enzyme immunoassay for the measurement of total 25-OH Vitamin D (Vitamin D2 and Vitamin D3) in both serum and plasma, will be a highlight of the 2014 American Association for Clinical Chemistry (AACC) Conference.
DRG International’s Renin (Active) ELISA for testing of active Renin in human EDTA plasma will be on display at the AACC’s 2014 show in Chicago, IL on July 27-31.
As a leading manufacturer of raw material for IVD industry, Fapon Biotech Inc. discovers, develops and provides innovative antigen, antibodies and enzymes that deliver significant benefits to IVD industry.
AACC released a position statement on newborn screening, the practice of testing every newborn for medical conditions that cause disabilities, developmental delays, or death.
On January 13, the New York State (NYS) Department of Health issued a directive limiting the ways in which NYS medical laboratories can use blood glucose meters to help patients. Although AACC shares the Department’s desire to ensure that blood glucose devices are used safely and appropriately, the association is concerned that this policy may impede the delivery of quality patient care and advises the Department to rescind it.
In March of this year, a team of Georgetown University scientists published research showing that, for the first time ever, a blood test has the potential to predict Alzheimer’s disease before patients start showing symptoms. AACC is pleased to announce that a late-breaking session at the 2014 AACC Annual Meeting & Clinical Lab Expo in Chicago will expand upon this groundbreaking research and discuss why it could be the key to curing this devastating illness.
In January, the U.S. Food and Drug Administration (FDA) released draft guidance proposing separate performance and accuracy criteria for over-the-counter blood glucose meters used in the home and prescription blood glucose meters used in hospitals. AACC supports FDA’s initiative to improve the quality of these devices and enhance patient care, but recommends revising this draft guidance to ensure that it does not unnecessarily increase the regulatory burden and costs on the healthcare system.
On May 7, AACC will host a webinar about the Protecting Access to Medicare Act of 2014, a new law signed by the president on April 1 that will make the most significant changes to medical test reimbursement that clinical laboratories have seen in 3 decades.
In November 2013, the U.S. Food and Drug Administration (FDA) ordered the company 23andMe to stop offering its direct-to-consumer DNA testing service, which provided individuals with $99 assessments of their genetic risk for almost 200 disorders. A thought-stimulating opinion piece published in Clinical Chemistry, the journal of AACC, now examines whether this move by FDA is a violation of the First Amendment, or a necessary step to protect consumers.
Though the 11 most popular hospital urine pregnancy tests perform well in the first month after conception, a new study published in Clinical Chemistry, the journal of AACC, reveals the alarming statistic that nine of these tests become significantly more likely to produce false-negative results after the 5th to 7th week of pregnancy.
On March 19, AACC will host a webinar with FDA division director Courtney Lias, PhD, about FDA’s new draft guidance proposing separate performance and accuracy criteria for over-the-counter blood glucose meters used in the home and prescription point-of-care blood glucose meters used in the hospital.
The President’s budget proposes cuts to laboratory reimbursement that could have a significant impact on patient health by hindering the development and implementation of new technologies, reducing the number of laboratories serving underserved populations, decreasing patient access to such vital tests as hepatitis C and cancer screenings, and diminishing the quality of testing.
On February 26, AACC will host a webinar with Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics in the Center for Devices and Radiological Health at FDA to discuss FDA’s guidance on in vitro diagnostic products labeled for research use only (RUO) or investigational use only (IUO).
AACC is pleased to announce the recipients of the 2014 AACC Awards. Each year, AACC recognizes individuals from around the world for their superior contributions to the field of laboratory medicine with its awards program, which aims to encourage excellence within the profession and raise awareness about the importance of clinical laboratory science to improving healthcare.
Today, HHS announced a ruling that allows patients direct access to their completed test reports. AACC supports this new ruling and applauds the ongoing efforts of HHS to empower patients to be informed healthcare consumers.
On January 29, the U.S. Senate passed the Newborn Screening Saves Lives Reauthorization Act of 2013 (S.1417) by unanimous consent. AACC applauds the Senate’s approval of this legislation, which is integral to improving children’s health, and urges the U.S. House of Representatives to pass it as well.
A new Q&A in the “Advancing Women’s Health” issue of Clinical Chemistry, the journal of AACC, explores the ethics of preimplantation genetic diagnosis, a form of genetic testing that has already made it possible for parents to conceive a child who is a donor match for a sick relative, who shares their minor disability (such as deafness), or to select gender.
The symptoms of heart disease are often less obvious in women than in men, and as a result, some experts have recommended changing current medical practice and using separate criteria to identify the disease and predict its progression in women. However, new findings in the “Advancing Women’s Health” issue of Clinical Chemistry, the journal of AACC, suggest that sex-specific criteria do not improve the prognostic accuracy of blood tests for diagnosing heart disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right